Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

123 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Eligibility NCT01134107 Diabetes Mellitus, Type 1 - Eligibility

- 27.09.21 - 1 Formulaire, 2 Groupes Item, 24 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01134107

Eligibility Diabetes NCT00605137

- 20.09.21 - 1 Formulaire, 2 Groupes Item, 12 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Safety of Insulin Detemir in Children With Type 1 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00605137

Eligibility NCT00974740 Type 1 Diabetes - Eligibility

- 20.09.21 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00974740

Eligibility Diabetes Mellitus, Type 1 NCT00063128

- 17.09.21 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.; ODM derived from: https://clinicaltrials.gov/show/NCT00063128

Eligibility Type 1 Diabetes Mellitus NCT00762671

- 17.09.21 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT00762671

Eligibility Type 1 Diabetes Mellitus NCT00761852

- 17.09.21 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Signaling Mechanisms and Vascular Function in Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT00761852

Eligibility Diabetes Mellitus, Type 1 NCT00722241

- 17.09.21 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System; ODM derived from: https://clinicaltrials.gov/show/NCT00722241

Eligibility NCT01103284 Type 1 Diabetes Mellitus - Eligibility

- 17.09.21 - 1 Formulaire, 2 Groupes Item, 7 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01103284

Eligibility Diabetes Mellitus, Type 1 NCT00406458

- 17.09.21 - 1 Formulaire, 1 Groupe Item, 14 Eléments de données, 1 Langue
Groupe Item: Criteria
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy; ODM derived from: https://clinicaltrials.gov/show/NCT00406458

Eligibility NCT00356109 Diabetes Mellitus, Type 1 - Eligibility

- 13.04.21 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00356109

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - IMD Report - Scleroderma or Morphea; Dermatomyositis or Polymyositis; Diabetes mellitus Type I (Report Final and Annex Report 2 Final)

- 02.11.20 - 1 Formulaire, 25 Groupes Item, 95 Eléments de données, 1 Langue
Groupes Item: Administrative, Scleroderma or Morphea, Scleroderma or Morphea - Signs and Symptoms, Scleroderma or Morphea - Other signs and symptoms, Scleroderma or Morphea - Other signs and symptoms , Scleroderma or Morphea - Diagnostic Test Results, Scleroderma or Morphea - Other Diagnostic Test Results , Scleroderma or Morphea - Other Diagnostic Test Results , Scleroderma or Morphea - Other diagnostic Procedure, Dermatomyositis or Polymyositis, Dermatomyositis or Polymyositis - Signs and symptoms (supporting the final diagnosis), Dermatomyositis or Polymyositis - Other Signs and symptoms, Dermatomyositis or Polymyositis - Other Signs and symptoms , Dermatomyositis or Polymyositis - Diagnostic Test Results, Dermatomyositis or Polymyositis - Other Diagnostic Test Results , Dermatomyositis or Polymyositis - Other Diagnostic Test Results , Dermatomyositis or Polymyositis - Other diagnostic Procedure , Diabetes mellitus type I, Diabetes mellitus type I - Signs and symptoms (supporting the final diagnosis), Diabetes mellitus type I - Other Signs and symptoms , Diabetes mellitus type I - Other Signs and symptoms , Diabetes mellitus type I - Diagnostic Test Results , Diabetes mellitus type I - Other Diagnostic Test Results , Diabetes mellitus type I - Other Diagnostic Test Results , Diabetes mellitus type I - Other diagnostic Procedure
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Eligibility Insulin Dependent Diabetes NCT01745900

- 21.04.20 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Evaluation and Comparison of Noninvasive Blood Glucose Concentrations; ODM derived from: https://clinicaltrials.gov/show/NCT01745900

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial